Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 11, 2023 08:00 ET | Source: SalioGen Therapeutics, inc.

SalioGen Therapeutics Appoints Jason F. Cole as Chief Executive Officer and Chairman of the Board of Directors

LEXINGTON, Mass., Sept. 11, 2023 (GLOBE NEWSWIRE) -- SalioGen Therapeutics, a privately held biotechnology company, today announced that its Board of Directors has appointed Jason F. Cole, J.D. as...
July 20, 2022 08:00 ET | Source: SalioGen Therapeutics, inc.

SalioGen Therapeutics Strengthens its Leadership Team to Advance its Gene Coding™ Platform

CAMBRIDGE, Mass., July 20, 2022 (GLOBE NEWSWIRE) -- SalioGen Therapeutics, a privately held biotechnology company developing Gene CodingTM, a new category of genetic medicine, today announced the...
January 05, 2022 08:00 ET | Source: SalioGen Therapeutics, inc.

SalioGen Therapeutics Closes $115 Million Oversubscribed Series B Financing to Advance Gene Coding™ – A New Category of Genetic Medicine

CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- SalioGen Therapeutics, a privately held biotechnology company developing Gene Coding™, a new category of genetic medicine, today announced the...
November 10, 2021 08:00 ET | Source: SalioGen Therapeutics, inc.

SalioGen Therapeutics Appoints Esteemed Industry Veterans to Executive Advisory Board

CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- SalioGen Therapeutics, a privately held biotechnology company developing the Gene CodingTM approach to genetic medicine, announced today the...
July 28, 2021 08:00 ET | Source: SalioGen Therapeutics, inc.

SalioGen Therapeutics Strengthens Management with Key Additions to Leadership Team to Advance Its Gene Coding Platform

- Sung You, M.S., MBA, appointed as Chief Business and Strategy Officer- Nancy L. Craig, Ph.D., appointed as Senior Vice President of Genetic Engineering and Mobile Elements- Sandeep Nema, Ph.D.,...
March 01, 2021 08:00 ET | Source: SalioGen Therapeutics, inc.

SalioGen Therapeutics Announces Closing of $20 Million Series A Financing to Support Advancing a Novel Genome Engineering Platform for Non-Viral Gene Therapy

Introducing a mammal-derived genome engineering enzyme for next-generation gene and cell therapy Financing to fund SalioGen’s pipeline in genetic diseases, based on proprietary EDIT ‘gene coding’...